Hello, everyone, and thank you all for joining us during the Lytham Partners Spring 2026 investor conference. My name is Ben Shamsian, Vice President of Lytham Partners, and today Brian Carrico, CEO of NeurAxis, will be taking us through a brief slide presentation. NeurAxis trades under NRXS. With that, let's get started. Brian, welcome. I will turn the floor over to you for your presentation. Thank you, Ben. Welcome back, everyone who's familiar with the story, and for those who are new, I look forward to covering high level a little bit about NeurAxis today and where we are, and then potentially having follow-up calls in the coming days and weeks ahead to answer more detailed questions. Again, as Ben said, Brian Carrico, President and CEO of NeurAxis, a publicly traded NRXS. This is a deck that's going to cover information through quarter one and some information that I've discussed on our recent earnings call, and we'll go up to the current date. This is titled May of 2026, and we'll go through the disclosure here. High level, who is NeurAxis? Well, we are a first-to-market growth stage med tech company focused on neuromodulation therapies for chronic and debilitating conditions in GI, specifically from disorders of gut-brain interaction in pediatrics and adults. We have today one pediatric indication that covers functional abdominal pain, functional dyspepsia, and nausea in children. We also have the adult version of those indications, but we're only commercializing today in the Veterans Administration, the VA hospitals, as far as adults, because we have an FSS contract there. We're commercializing the pediatric space where we have really strong insurance policy coverage and a Category 1 CPT code, which we'll discuss, and in the adult VA market. A few high-level overview points here. We just secured our Category 1 CPT code, which became effective January 1st. For those of you who are familiar with med tech, a Category 1 CPT code streamlines billing and RVUs. RVUs are how physicians are measured on their productivity, and the billing from a Category 1 CPT code makes it much easier to bill for children's hospitals. We have over 100 million children's hospitals on the commercial insurance policy coverage now. We have significantly more than that, including Medicaid, now that there's a Category 1 CPT code. We have talked about our 2025 revenue of a little over $3 million. We've just announced that our quarter one was a record. We had $1.6 million in quarter one of revenue. Our gross margins were, I believe, about 86% in the quarter. We expect those to continue to grow as we get more insurance policy coverage. From a timeline and pipeline standpoint, I just covered the indications that we have now. We can talk on future dates about the ongoing indications and the upcoming potential indications in the pediatric and adult space. A few highlights about the technology. I've said for years, if you've followed along, that strong data brings strong policy coverage and reimbursement, and that creates strong revenue growth. We've got a very large total addressable market and therefore a serviceable available market in both the pediatric and the adult space. We went through the FDA De Novo clearance pathway, which means we were first to market. That brought us then our Category 1 CPT billing code, and then major insurance policy coverage has followed that, including Anthem at the end of 2025, which has been a nice start to our 2026. A few pieces of our indications here. Functional abdominal pain and functional dyspepsia collectively bring us about a $5 billion serviceable available market. In the adult space, we have the adult version of functional abdominal pain, IBS, and functional dyspepsia, which is about a $12 billion market opportunity. RED, which is our rectal expulsion technology, is about a $2 billion market opportunity. What are we doing? High level, I won't get into too many details today from the science; we're treating disorders of the gut-brain interaction. This is where functional dyspepsia, irritable bowel syndrome, and eventually, we believe, cyclic vomiting syndrome will be a future indication for us in the next 12 - 24 months. We are treating these disorders of the gut-brain interaction, targeting the vagus nerve. In layman's terms, the brain and the gut are talking to each other, and although the pain is in the gut, the brain is responsible for this and vice versa. These DGBIs are a problem with an unmet need, especially in pediatrics. We are the first to market. There were no, and there still are no, FDA-approved therapies for children with these conditions. These kids are missing school, they're missing sports, they're missing social activities. The drugs they've been given are off-label. They oftentimes have black box label warnings from the FDA. Two recent studies show antidepressant use in adults is increasing all-cause morbidity. A second study is showing that the antidepressant use in adults is causing sudden cardiac arrest. If that is happening to adults, what are we doing giving these to children? That's been the push, to get away from these drugs and more into an integrative health program where IB-Stim can be utilized up front. The technology high level is $1,195 per device. We have gross margins of a little over 90%. When we talk about our margins that we've reported, that's because we have some research devices. We have a patient assistance program that brings those margins down. Each patient needs four devices, so that's $4,780, almost $5,000 per patient when approved by insurance. This device is placed on a Monday, for example, and taken off on a Saturday. The patient comes back two days later and has a second device placed, and so on and so forth for four weeks. Four weeks of therapy, and then we have statistically significant data at 12 months in multiple studies showing long-term relief. This slide highlights the foundation of who we are. We have 16 current publications utilizing the NeurAxis technology and 10 different types of research at 13 different children's hospitals. This is the foundation of why we've been so successful with insurance policy coverage and with the academic societies and with the children's hospitals as we grow and begin to become more comprehensive in these children's hospitals with growth and revenue. How does this neuromodulation work? High level, we're gaining direct access through the cranial nerves of the auricle. We're gaining direct access to the central nervous system through these peripheral cranial nerves. We're stimulating these nerves and therefore reducing the firing of the amygdala. The amygdala is the part of the brain that is overstimulated and therefore causing these pain signals in the gut, in the stomach. In long term, what we're doing with this stimulation is we're inducing changes in brain pathways and connectivity, and positively bringing these patients back to a level of normal or homeostasis. This is a quick slide on the standard pharmacotherapy in children showing the dangers, the amitriptyline, SSRIs, the increased risk of suicidal ideation, the weight gain, the long-term risk of dementia shown recently in adults with using amitriptyline. These are dangerous drugs in adults and very dangerous in children for a developing brain. This is all part of the push to take something that's evidence-based in IB-Stim. Side effects are virtually non-existent and allow us to treat these patients safely and effectively upfront before they start medications. We have done a couple things from a go-to-market standpoint. Right now, we have a W2 sales force, and we have 17 insurance policy coverages on the commercial side. That doesn't include Medicaid or managed Medicaid, and we're just over 100 million covered lives. We are currently calling on 260 children's hospitals in the country, and the category 1 code, as I mentioned, was effective on January 1st. High level, the go-to-market strategy is we have W2 salespeople that are calling on both VAs and children's hospitals, and we'll continue to expand that commercial footprint. We've just recently hired a digital. Well, we have a vice president of marketing, and that was hired about a year ago, and then we just hired a digital marketing expert who was at a small med tech company that exited to Boston Scientific, and now he's come over to work with NeurAxis. We've also added to the commercial footprint. In addition to salespeople, we're adding medical science liaisons. We just hired a psychologist with her doctorate to help implement these integrative health programs in the children's hospitals and grow utilization and grow depth on our current accounts. The commercial footprint is expanding. Quarter one was very helpful and told us with the Category 1 CPT code what works and what doesn't and where we can put resources to get the maximum growth opportunity and treat more children. IP portfolio runs through 2039 as of now. We're doing some things to significantly extend that IP portfolio and advance the technology, which we won't talk about today, but we will in coming quarters. Our board of directors and then back to our key investment highlights. Right now, we are really focused on growing the remaining insurance policy coverage and expanding the commercial footprint. Those are the two focus points. There are a lot of things that we're working on, but nothing is more important than finalizing the remaining commercial insurance payers throughout the country. Number two, expanding the commercial footprint to make sure we have the resources necessary to drive utilization in the 260 children's hospitals and in the 180 VA hospitals, to maximize the opportunity and help as many people in those systems as possible. Our RED device, we can touch briefly on this—is a Rectal Expulsion Device. This technology was paused. We recently learned that the billing and coding for this was worked out in the last couple of weeks. We can now begin to commercialize this as we were last year. We were gaining some nice momentum at the end of 2025 before the category 1 CPT code situation paused the commercialization. We'll be able to take this back to market now. We'll update the coding on this as we get the coding and billing guide updated in the coming weeks. From a capital structure standpoint, this is as of March 31st. The share price as of May 8th was $8.20. On March 31st, we had 11.5 million outstanding shares, 1.2 million warrants, and 2.6 million options in RSUs. There were 3.8 million Series B preferred with a fully diluted cap table of 19 million. Financial position as of March 31st was $7.1 million. We've got slightly more than that now. As you heard on the Q1 earnings call, I think we burned just over $1 million, which is down from $1.5 million or $1.6 million or $1.7 million in Q4 last year. The cash burn is coming down. Of course, it could increase a little bit here with these new hires on the commercial footprint. As a general rule, with this amount of cash, we have significant runway from a cash standpoint. High level, this was an outstanding first quarter, and I guess we're still probably seven or eight weeks away from announcing quarter two, which we're still in the middle of. I look forward to speaking to everyone at a high level and in more detail on one-on-ones, and we'll take it from there. Ben? Thanks, Brian. Thanks, everyone, for watching. If you have any questions or would like to schedule a meeting with NeurAxis, please send me an email at shamsian@lythampartners.com. If you'd like to learn more about Lytham Partners, please visit our website at lythampartners.com or follow us on LinkedIn to stay connected about future events. We hope you all enjoy the rest of the conference and have a great rest of the day.